BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27998118)

  • 21. Scalable Production of HPV16 L1 Protein and VLPs from Tobacco Leaves.
    Zahin M; Joh J; Khanal S; Husk A; Mason H; Warzecha H; Ghim SJ; Miller DM; Matoba N; Jenson AB
    PLoS One; 2016; 11(8):e0160995. PubMed ID: 27518899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding.
    Ishii Y; Ozaki S; Tanaka K; Kanda T
    Virus Genes; 2005 Dec; 31(3):321-8. PubMed ID: 16175337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
    Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
    Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16.
    El Mehdaoui S; Touzé A; Laurent S; Sizaret PY; Rasschaert D; Coursaget P
    J Virol; 2000 Nov; 74(22):10332-40. PubMed ID: 11044077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of human papillomavirus type 6 L1 and L2 isolated in China and self assembly of virus-like particles by the products.
    Wang M; Wang LL; Chen LF; Han YH; Zou YH; Si JY; Song GX
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jan; 35(1):27-34. PubMed ID: 12518224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.
    Chen XS; Garcea RL; Goldberg I; Casini G; Harrison SC
    Mol Cell; 2000 Mar; 5(3):557-67. PubMed ID: 10882140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Papillomavirus-like particle vaccines.
    Schiller JT; Lowy DR
    J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.
    Baek JO; Seo JW; Kim IH; Kim CH
    Protein Expr Purif; 2011 Feb; 75(2):211-7. PubMed ID: 20716445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus type 16 and 18 L1 protein peptide binding to VERO and HeLa cells inhibits their VLPs binding.
    Vera-Bravo R; Ocampo M; Urquiza M; García JE; Rodríguez LE; Puentes A; López R; Curtidor H; Suárez JE; Torres E; Guzmán F; Díaz D; Cortes J; Bravo MM; Cómbita AL; Orozco O; Patarroyo ME
    Int J Cancer; 2003 Nov; 107(3):416-24. PubMed ID: 14506742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells.
    Kim HJ; Cho SY; Park MH; Kim HJ
    Arch Pharm Res; 2018 May; 41(5):544-553. PubMed ID: 29637494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-Assembling Plant-Derived Vaccines Against Papillomaviruses.
    Noris E
    Methods Mol Biol; 2018; 1776():85-95. PubMed ID: 29869236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
    Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
    Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in Escherichia coli.
    Wang D; Fan F; Li Z; Liu X; Song S; Wei S; He M; Lin Y; Li Z; Wei M; Yu H; Gu Y; Li S; Xia N
    Protein Expr Purif; 2017 May; 133():110-120. PubMed ID: 28267627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles.
    Heino P; Dillner J; Schwartz S
    Virology; 1995 Dec; 214(2):349-59. PubMed ID: 8553535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation.
    de Witte L; Zoughlami Y; Aengeneyndt B; David G; van Kooyk Y; Gissmann L; Geijtenbeek TB
    Immunobiology; 2007; 212(9-10):679-91. PubMed ID: 18086370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.